Roche's Tecentriq Gets EU Approval as Adjuvant Treatment for Cancer Type
June 09 2022 - 1:54AM
Dow Jones News
By Cristina Roca
Roche Holding AG said Thursday that its tecentriq immunotherapy
drug has been approved in the European Union as an additional
treatment for some adults with early-stage non-small cell lung
cancer.
The European Commission approved the treatment for patients who
had complete resection and platinum-based chemotherapy, among other
criteria.
"Since approximately half of all people with early NSCLC develop
recurrence after surgery, which in some cases is no longer curable,
treating this cancer at an earlier stage offers the best chance to
prevent recurrence," Roche Chief Medical Officer Levi Garraway
said.
Interim data of a Phase 3 study showed that treatment with
tecentriq reduced the risk of disease recurrence or death by
57%.
Tecentriq is already approved as an adjuvant treatment in 19
countries.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
June 09, 2022 01:39 ET (05:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024